The VE-BASKET study, a non-randomized open label multicohort study of several BRAF V600E mutant central nervous system tumors, showed efficacy of vemurafenib treatment, especially in PXA [40]. This evidence concerns the gene BRAF and pleomorphic xanthoastrocytoma.